Cinclus Pharma Holding Past Earnings Performance
Past criteria checks 0/6
Cinclus Pharma Holding's earnings have been declining at an average annual rate of -6.5%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 1373.9% per year.
Key information
-6.47%
Earnings growth rate
14.20%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.53% |
| Revenue growth rate | 1,373.93% |
| Return on equity | -85.06% |
| Net Margin | -354.14% |
| Next Earnings Update | 19 Aug 2026 |
Recent past performance updates
Recent updates
CINPHA: Phase III GERD Progress Will Drive Future Upside Potential
Analysts now set a price target of SEK46.25 for Cinclus Pharma Holding, down from SEK53.33. This reflects updated assumptions for faster revenue growth of 19.07%, a slightly higher profit margin of 20.05% and a lower future P/E of 108.86x.CINPHA: FDA Green Light For Single Pivotal Trial Will Drive Upside
Analysts have adjusted their price target on Cinclus Pharma Holding to SEK53.33 from SEK55, reflecting updates to fair value assumptions, growth expectations, margins and a higher projected future P/E multiple. What's in the News The FDA confirms that a single pivotal study supported by additional evidence will be the new standard for US drug approvals, and Cinclus Pharma's current Phase III program for erosive GERD is described as a sufficient basis for a future US regulatory submission (Key Developments).
CINPHA: Upcoming Phase III GERD Results Will Drive Future Upside Potential
Analysts have trimmed their price target on Cinclus Pharma Holding to SEK 40 from SEK 50, reflecting updated assumptions for revenue growth, profit margins, discount rate, and future P/E multiples. What's in the News The FDA clarifies that a single adequate and well controlled pivotal study with supportive evidence will be the new standard for US drug approvals, including for common diseases, and confirms Cinclus Pharma's current Phase III program in erosive GERD as a sufficient basis for a US regulatory submission (company announcement).CINPHA: FDA Guidance Will Support Pivotal Phase III Trial Momentum
Analysts have adjusted their price target for Cinclus Pharma Holding, keeping it at SEK 55.00 per share. Updated forecasts indicate a more cautious outlook for revenue growth, but there is a slight improvement in expected profit margins.CINPHA: Clear FDA Guidance Will Drive Late-Stage Trial Progress
Narrative Update on Cinclus Pharma Holding Analysts have maintained their price target for Cinclus Pharma Holding at SEK 55.00. They noted only minor updates to profit margin and discount rate projections, with no change to their fair value estimate.Advancing Late-Stage GERD Studies Will Drive Substantial Long-Term Upside
Analysts have maintained their price target for Cinclus Pharma Holding at SEK 55.00, citing ongoing expectations for strong profit margins and sustained valuation multiples. What's in the News Cinclus Pharma received positive feedback from the U.S. Food and Drug Administration (FDA) on its Chemistry, Manufacturing, and Controls (CMC) strategy.PCAB Pipeline Will Revolutionize Severe GERD Treatment Globally
Analysts have revised their price target for Cinclus Pharma Holding downwards from SEK 61.67 to SEK 55.00. This change reflects updated views on revenue growth potential and profit margin projections.PCAB Pipeline Will Revolutionize Severe GERD Treatment Globally
Key Takeaways Innovative drug formulation, strong market demand, and strategic partnerships position Cinclus Pharma for significant revenue and margin growth in both domestic and international markets. Retention of global commercial rights enables flexible licensing or direct launch strategies, supporting long-term earnings potential through multiple income streams.Here's Why We're Not Too Worried About Cinclus Pharma Holding's (STO:CINPHA) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Cinclus Pharma Holding (STO:CINPHA) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Revenue & Expenses Breakdown
How Cinclus Pharma Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 68 | -239 | 59 | 251 |
| 31 Dec 25 | 57 | -184 | 57 | 198 |
| 30 Sep 25 | 48 | -177 | 50 | 191 |
| 30 Jun 25 | 39 | -173 | 50 | 178 |
| 31 Mar 25 | 5 | -165 | 39 | 145 |
| 31 Dec 24 | 5 | -168 | 37 | 137 |
| 30 Sep 24 | 0 | -158 | 36 | 117 |
| 30 Jun 24 | 0 | -183 | 37 | 139 |
| 31 Mar 24 | 3 | -203 | 33 | 158 |
| 31 Dec 23 | 6 | -215 | 40 | 167 |
| 31 Dec 22 | 11 | -249 | 64 | 157 |
| 31 Dec 21 | 0 | -76 | 14 | 70 |
| 31 Dec 20 | 0 | -43 | 3 | 37 |
Quality Earnings: CINPHA is currently unprofitable.
Growing Profit Margin: CINPHA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CINPHA is unprofitable, and losses have increased over the past 5 years at a rate of 6.5% per year.
Accelerating Growth: Unable to compare CINPHA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CINPHA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.3%).
Return on Equity
High ROE: CINPHA has a negative Return on Equity (-85.06%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/16 00:55 |
| End of Day Share Price | 2026/06/16 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cinclus Pharma Holding AB (publ) is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ulrik Trattner | DNB Carnegie |
| Fredrik Thor | Redeye |
| Kevin Sule | Redeye |